Rachel Hevey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Rachel Hevey has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Chang-Chun Ling
Department of Chemistry, University of Calgary, 2500 University Drive NW, Calgary, AB T2N 1N4, Canada
6 shared publications - Alexander R. Bennett
Department of Medical Biochemistry, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden
2 shared publications - Beat Ernst
Department of Pharmaceutical Sciences, Group Molecular Pharmacy, Pharmazentrum, University of Basel, Klingelbergstrasse 50, Basel CH-4056, Switzerland
2 shared publications Carmen R. Cori
Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
2 shared publicationsChang-Chun Ling
Alberta Glycomics Centre, Department of Chemistry, University of Calgary, Calgary, AB, T2N 1N4, Canada
2 shared publications- Daniel Bojar
Department of Chemistry and Molecular Biology, University of Gothenburg, Gothenburg, Sweden
2 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10067
Seal milk oligosaccharides rival human milk complexity and exhibit functional dynamics during lactation
Milk oligosaccharides are crucial for neonatal development and health in mammals. Yet most milk research focuses on humans, or on domesticated mammals that are poor in milk oligosaccharide complexity. Here, we perform an exhaustive mass spectrometry-driven structural characterization of milk oligosaccharides in a wild mammal, female Atlantic grey seals ( Halichoerus grypus ), throughout their lactation period. Characterizing and quantifying 332 milk oligosaccharides, including 166 unreported structures, we reveal seals to rival human milk in complexity. We report seal free oligosaccharides to reach up to 28 monosaccharides in size. Paired glycomics and metabolomics time course analysis establishes a concerted regulatory process reshaping the seal milk glycome throughout lactation, similar to human milk. Functional analysis of the structures we here characterized reveals anti-biofilm effects and immunomodulatory functions of seal milk oligosaccharides. Our findings challenge long-held assumptions about milk complexity of non-human mammals and enable insights into the functional relevance of complex carbohydrates in milk.
- 25 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10067
Open AccessSeal milk oligosaccharides rival human milk complexity and exhibit functional dynamics during lactation
Milk oligosaccharides are crucial for neonatal development and health in mammals. Yet most milk research focuses on humans, or on domesticated mammals that are poor in milk oligosaccharide complexity. Here, we perform an exhaustive mass spectrometry-driven structural characterization of milk oligosaccharides in a wild mammal, female Atlantic grey seals ( Halichoerus grypus ), throughout their lactation period. Characterizing and quantifying 332 milk oligosaccharides, including 166 unreported structures, we reveal seals to rival human milk in complexity. We report seal free oligosaccharides to reach up to 28 monosaccharides in size. Paired glycomics and metabolomics time course analysis establishes a concerted regulatory process reshaping the seal milk glycome throughout lactation, similar to human milk. Functional analysis of the structures we here characterized reveals anti-biofilm effects and immunomodulatory functions of seal milk oligosaccharides. Our findings challenge long-held assumptions about milk complexity of non-human mammals and enable insights into the functional relevance of complex carbohydrates in milk.
- Open Access
Seal milk oligosaccharides rival human milk complexity and exhibit functional dynamics during lactation
Breast milk oligosaccharides are crucial for neonatal development and health. Yet most milk research focuses on humans, or domesticated mammals that are historically poor in milk oligosaccharide complexity. Here, we perform an exhaustive mass spectrometry-driven structural characterization of milk oligosaccharides in a wild mammal, Atlantic grey seals ( Halichoerus grypus ), throughout their lactation period. Characterizing and quantifying 332 milk oligosaccharides, including 166 novel structures, we reveal seals to rival human milk in complexity, with seal free oligosaccharides reaching unprecedented 28 monosaccharides in size. Glycomics and metabolomics time course analysis establishes a concerted regulatory process reshaping the seal milk glycome throughout lactation,similar as in human milk. Functional analysis of herein newly characterized structures reveals anti-biofilm effects and immunomodulatory functions of seal milk oligosaccharides. We envision these findings to overturn long-held assumptions about milk complexity of non-human mammals and enable insights into the functional relevance of complex carbohydrates in breast milk.
Open AccessSeal milk oligosaccharides rival human milk complexity and exhibit functional dynamics during lactation
Breast milk oligosaccharides are crucial for neonatal development and health. Yet most milk research focuses on humans, or domesticated mammals that are historically poor in milk oligosaccharide complexity. Here, we perform an exhaustive mass spectrometry-driven structural characterization of milk oligosaccharides in a wild mammal, Atlantic grey seals ( Halichoerus grypus ), throughout their lactation period. Characterizing and quantifying 332 milk oligosaccharides, including 166 novel structures, we reveal seals to rival human milk in complexity, with seal free oligosaccharides reaching unprecedented 28 monosaccharides in size. Glycomics and metabolomics time course analysis establishes a concerted regulatory process reshaping the seal milk glycome throughout lactation,similar as in human milk. Functional analysis of herein newly characterized structures reveals anti-biofilm effects and immunomodulatory functions of seal milk oligosaccharides. We envision these findings to overturn long-held assumptions about milk complexity of non-human mammals and enable insights into the functional relevance of complex carbohydrates in breast milk.
- Open Access
- 3 January 2025
- Published by Beilstein Institut in Beilstein Journal of Organic Chemistry
- Vol. 21 (1) , 8-9
Chemical glycobiology
- 3 January 2025
- Published by Beilstein Institut in Beilstein Journal of Organic Chemistry
- Vol. 21 (1) , 8-9
Open AccessChemical glycobiology
- Open Access
- 3 May 2024
- Published by Wiley in Helvetica Chimica Acta
- Vol. 107 (7) , e202400026
Total Synthesis of Core 3 & Core 4‐Type Mucin Glycan Derivatives
Recent studies have demonstrated the ability of mucin O‐glycans to attenuate virulence in diverse, cross‐kingdom pathogens, sparking interest in their development as a novel therapeutic approach against infection. Although their virulence attenuating activity is evident, mucin glycans obtained from native sources comprise mixtures of several hundred distinct structures, and therefore the specific active glycan epitopes and molecular mechanisms of virulence attenuation remain unclear. Individual mucin glycan structures cannot be purified from native sources and are not amenable to automated synthesis; therefore, to further investigate the phenomena of virulence attenuation we have been developing convergent and scalable methods (>30 mg per target glycan) to assemble a mucin O‐glycan library in sufficient scale and purity to facilitate biological studies. Previously we described a method to obtain core 1 & core 2‐type mucin glycan derivatives that have since been used to identify active epitopes in Candida albicans and Vibrio cholerae. In the current study, we describe the expansion of our glycan library to include core 3 & core 4‐type derivatives, increasing the structural diversity of our platform for biological evaluation.
- 3 May 2024
- Published by Wiley in Helvetica Chimica Acta
- Vol. 107 (7) , e202400026
Open AccessTotal Synthesis of Core 3 & Core 4‐Type Mucin Glycan Derivatives
Recent studies have demonstrated the ability of mucin O‐glycans to attenuate virulence in diverse, cross‐kingdom pathogens, sparking interest in their development as a novel therapeutic approach against infection. Although their virulence attenuating activity is evident, mucin glycans obtained from native sources comprise mixtures of several hundred distinct structures, and therefore the specific active glycan epitopes and molecular mechanisms of virulence attenuation remain unclear. Individual mucin glycan structures cannot be purified from native sources and are not amenable to automated synthesis; therefore, to further investigate the phenomena of virulence attenuation we have been developing convergent and scalable methods (>30 mg per target glycan) to assemble a mucin O‐glycan library in sufficient scale and purity to facilitate biological studies. Previously we described a method to obtain core 1 & core 2‐type mucin glycan derivatives that have since been used to identify active epitopes in Candida albicans and Vibrio cholerae. In the current study, we describe the expansion of our glycan library to include core 3 & core 4‐type derivatives, increasing the structural diversity of our platform for biological evaluation.
- 23 December 2022
- Published by Wiley in Helvetica Chimica Acta
- Vol. 106 (1)
Carbohydrate‐Derived Dienes as Building Blocks for Pharmaceutically Relevant Molecules
Carbohydrate‐based dienes are valuable building blocks for a variety of highly functionalized carbo‐ and oxa‐cycles by virtue of their high degree of inherent stereochemical information, and suitability in various synthetic transformations. Research into the chemistry of carbohydrate‐based dienes has been expanding over the last decades due to its unique applications in the construction of diverse and complex structural frameworks. In this review, we describe the main transformations of this interesting class of molecule and highlight their utility in the construction of diverse ring systems important for drug development.
- 23 December 2022
- Published by Wiley in Helvetica Chimica Acta
- Vol. 106 (1)
Carbohydrate‐Derived Dienes as Building Blocks for Pharmaceutically Relevant Molecules
Carbohydrate‐based dienes are valuable building blocks for a variety of highly functionalized carbo‐ and oxa‐cycles by virtue of their high degree of inherent stereochemical information, and suitability in various synthetic transformations. Research into the chemistry of carbohydrate‐based dienes has been expanding over the last decades due to its unique applications in the construction of diverse and complex structural frameworks. In this review, we describe the main transformations of this interesting class of molecule and highlight their utility in the construction of diverse ring systems important for drug development.
- Open Access
- 12 December 2022
- Published by Springer Nature in The EMBO Journal
- Vol. 42 (3) , e111562
Host‐derived O‐glycans inhibit toxigenic conversion by a virulence‐encoding phage in Vibrio cholerae
Pandemic and endemic strains of Vibrio cholerae arise from toxigenic conversion by the CTXφ bacteriophage, a process by which CTXφ infects nontoxigenic strains of V. cholerae. CTXφ encodes the cholera toxin, an enterotoxin responsible for the watery diarrhea associated with cholera infections. Despite the critical role of CTXφ during infections, signals that affect CTXφ‐driven toxigenic conversion or expression of the CTXφ‐encoded cholera toxin remain poorly characterized, particularly in the context of the gut mucosa. Here, we identify mucin polymers as potent regulators of CTXφ‐driven pathogenicity in V. cholerae. Our results indicate that mucin‐associated O‐ glycans block toxigenic conversion by CTXφ and suppress the expression of CTXφ‐related virulence factors, including the toxin co‐regulated pilus and cholera toxin, by interfering with the TcpP/ToxR/ToxT virulence pathway. By synthesizing individual mucin glycan structures de novo , we identify the Core 2 motif as the critical structure governing this virulence attenuation. Overall, our results highlight a novel mechanism by which mucins and their associated O ‐glycan structures affect CTXφ‐mediated evolution and pathogenicity of V. cholerae , underscoring the potential regulatory power housed within mucus .
- 12 December 2022
- Published by Springer Nature in The EMBO Journal
- Vol. 42 (3) , e111562
Open AccessHost‐derived O‐glycans inhibit toxigenic conversion by a virulence‐encoding phage in Vibrio cholerae
Pandemic and endemic strains of Vibrio cholerae arise from toxigenic conversion by the CTXφ bacteriophage, a process by which CTXφ infects nontoxigenic strains of V. cholerae. CTXφ encodes the cholera toxin, an enterotoxin responsible for the watery diarrhea associated with cholera infections. Despite the critical role of CTXφ during infections, signals that affect CTXφ‐driven toxigenic conversion or expression of the CTXφ‐encoded cholera toxin remain poorly characterized, particularly in the context of the gut mucosa. Here, we identify mucin polymers as potent regulators of CTXφ‐driven pathogenicity in V. cholerae. Our results indicate that mucin‐associated O‐ glycans block toxigenic conversion by CTXφ and suppress the expression of CTXφ‐related virulence factors, including the toxin co‐regulated pilus and cholera toxin, by interfering with the TcpP/ToxR/ToxT virulence pathway. By synthesizing individual mucin glycan structures de novo , we identify the Core 2 motif as the critical structure governing this virulence attenuation. Overall, our results highlight a novel mechanism by which mucins and their associated O ‐glycan structures affect CTXφ‐mediated evolution and pathogenicity of V. cholerae , underscoring the potential regulatory power housed within mucus .
- Open Access
- 26 July 2022
- Published by Wiley in ChemistryOpen
- Vol. 12 (5)
Synthesis of Mucin O‐Glycans Associated with Attenuation of Pathogen Virulence
With the concerning rise in antibiotic‐resistant infections, novel treatment options against pathogens are urgently sought. Several recent studies have identified mucin O‐glycan mixtures as potent down‐regulators of virulence‐related gene expression in diverse pathogens. As individual mucin glycans cannot be isolated in sufficient purity and quantity for biological evaluation of discrete structures, we have developed an optimized synthetic approach to generate a small library of mucin glycans which were identified as most likely to display activity. The glycans have been prepared in sufficient quantity to assess biological function, studies of which are currently ongoing.
- 26 July 2022
- Published by Wiley in ChemistryOpen
- Vol. 12 (5)
Open AccessSynthesis of Mucin O‐Glycans Associated with Attenuation of Pathogen Virulence
With the concerning rise in antibiotic‐resistant infections, novel treatment options against pathogens are urgently sought. Several recent studies have identified mucin O‐glycan mixtures as potent down‐regulators of virulence‐related gene expression in diverse pathogens. As individual mucin glycans cannot be isolated in sufficient purity and quantity for biological evaluation of discrete structures, we have developed an optimized synthetic approach to generate a small library of mucin glycans which were identified as most likely to display activity. The glycans have been prepared in sufficient quantity to assess biological function, studies of which are currently ongoing.
- 6 June 2022
- Published by Springer Nature in Nature Chemical Biology
- Vol. 18 (7) , 762-773
Mucin O-glycans are natural inhibitors of Candida albicans pathogenicity
Mucins are large gel-forming polymers inside the mucus barrier that inhibit the yeast-to-hyphal transition of Candida albicans, a key virulence trait of this important human fungal pathogen. However, the molecular motifs in mucins that inhibit filamentation remain unclear despite their potential for therapeutic interventions. Here, we determined that mucins display an abundance of virulence-attenuating molecules in the form of mucin O-glycans. We isolated and cataloged >100 mucin O-glycans from three major mucosal surfaces and established that they suppress filamentation and related phenotypes relevant to infection, including surface adhesion, biofilm formation and cross-kingdom competition between C. albicans and the bacterium Pseudomonas aeruginosa. Using synthetic O-glycans, we identified three structures (core 1, core 1 + fucose and core 2 + galactose) that are sufficient to inhibit filamentation with potency comparable to the complex O-glycan pool. Overall, this work identifies mucin O-glycans as host molecules with untapped therapeutic potential to manage fungal pathogens.
- 6 June 2022
- Published by Springer Nature in Nature Chemical Biology
- Vol. 18 (7) , 762-773
Mucin O-glycans are natural inhibitors of Candida albicans pathogenicity
Mucins are large gel-forming polymers inside the mucus barrier that inhibit the yeast-to-hyphal transition of Candida albicans, a key virulence trait of this important human fungal pathogen. However, the molecular motifs in mucins that inhibit filamentation remain unclear despite their potential for therapeutic interventions. Here, we determined that mucins display an abundance of virulence-attenuating molecules in the form of mucin O-glycans. We isolated and cataloged >100 mucin O-glycans from three major mucosal surfaces and established that they suppress filamentation and related phenotypes relevant to infection, including surface adhesion, biofilm formation and cross-kingdom competition between C. albicans and the bacterium Pseudomonas aeruginosa. Using synthetic O-glycans, we identified three structures (core 1, core 1 + fucose and core 2 + galactose) that are sufficient to inhibit filamentation with potency comparable to the complex O-glycan pool. Overall, this work identifies mucin O-glycans as host molecules with untapped therapeutic potential to manage fungal pathogens.
- 2 November 2020
- Published by Wiley in British Journal of Pharmacology
- Vol. 178 (14) , 2802-2822
Sweet turning bitter: Carbohydrate sensing of complement in host defence and disease
The complement system plays a major role in threat recognition and in orchestrating responses to microbial intruders and accumulating debris. This immune surveillance is largely driven by lectins that sense carbohydrate signatures on foreign, diseased, and healthy host cells and act as complement activators, regulators, or receptors to shape appropriate immune responses. While carbohydrate sensing protects our bodies, misguided or impaired recognition can contribute to disease. Moreover, pathogenic microbes have evolved to evade complement by mimicking host signatures. While complement is recognized as a disease factor, we only slowly start to appreciate the role of carbohydrate interactions in the underlying processes. A better understanding of complement’s sweet side will contribute to a better description of disease mechanisms and enhanced diagnostic and therapeutic options. This review introduces the key components in complement‐mediated carbohydrate sensing, discusses their role in health and disease, and touches on the potential impact of carbohydrate‐related disease intervention.
- 2 November 2020
- Published by Wiley in British Journal of Pharmacology
- Vol. 178 (14) , 2802-2822
Sweet turning bitter: Carbohydrate sensing of complement in host defence and disease
The complement system plays a major role in threat recognition and in orchestrating responses to microbial intruders and accumulating debris. This immune surveillance is largely driven by lectins that sense carbohydrate signatures on foreign, diseased, and healthy host cells and act as complement activators, regulators, or receptors to shape appropriate immune responses. While carbohydrate sensing protects our bodies, misguided or impaired recognition can contribute to disease. Moreover, pathogenic microbes have evolved to evade complement by mimicking host signatures. While complement is recognized as a disease factor, we only slowly start to appreciate the role of carbohydrate interactions in the underlying processes. A better understanding of complement’s sweet side will contribute to a better description of disease mechanisms and enhanced diagnostic and therapeutic options. This review introduces the key components in complement‐mediated carbohydrate sensing, discusses their role in health and disease, and touches on the potential impact of carbohydrate‐related disease intervention.
- 9 September 2020
- Published by Wiley in Chemistry – A European Journal
- Vol. 27 (7) , 2240-2253
The Role of Fluorine in Glycomimetic Drug Design
Glycans are well established to play important roles at various stages of infection and disease, and ways to modulate these interactions have been sought as novel therapies. The use of native glycan structures has met with limited success, which can be attributed to their characteristic high polarity (e.g., low binding affinities) and inherently poor pharmacokinetic properties (e.g., short drug–target residence times, rapid renal excretion), leading to the development of ′glycomimetics′. Fluorinated drugs have become increasingly common over recent decades, with fluorinated glycomimetics offering some unique advantages. Deoxyfluorination maintains certain electrostatic interactions, while concomitantly reducing net polarity through ′polar hydrophobicity′, improving residence times and binding affinities. Fluorination destabilizes the oxocarbenium transition state associated with metabolic degradation, and can restore exo‐ and endo‐anomeric effects in C‐glycosides and carbasugars. Lastly, it has shown great utility in radiotracer development and enhancement of antigenicity in glycan‐based vaccines. Owing to synthetic challenges, fluorinated glycomimetics have been somewhat underutilized to date, but methodological improvements will advance their use in glycomimetic drugs.
- 9 September 2020
- Published by Wiley in Chemistry – A European Journal
- Vol. 27 (7) , 2240-2253
The Role of Fluorine in Glycomimetic Drug Design
Glycans are well established to play important roles at various stages of infection and disease, and ways to modulate these interactions have been sought as novel therapies. The use of native glycan structures has met with limited success, which can be attributed to their characteristic high polarity (e.g., low binding affinities) and inherently poor pharmacokinetic properties (e.g., short drug–target residence times, rapid renal excretion), leading to the development of ′glycomimetics′. Fluorinated drugs have become increasingly common over recent decades, with fluorinated glycomimetics offering some unique advantages. Deoxyfluorination maintains certain electrostatic interactions, while concomitantly reducing net polarity through ′polar hydrophobicity′, improving residence times and binding affinities. Fluorination destabilizes the oxocarbenium transition state associated with metabolic degradation, and can restore exo‐ and endo‐anomeric effects in C‐glycosides and carbasugars. Lastly, it has shown great utility in radiotracer development and enhancement of antigenicity in glycan‐based vaccines. Owing to synthetic challenges, fluorinated glycomimetics have been somewhat underutilized to date, but methodological improvements will advance their use in glycomimetic drugs.